Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
3,182,163
-
Total 13F shares
-
40,303,060
-
Share change
-
+7,544,748
-
Total reported value
-
$54,404,729
-
Put/Call ratio
-
2.5%
-
Price per share
-
$1.35
-
Number of holders
-
48
-
Value change
-
+$10,301,382
-
Number of buys
-
19
-
Number of sells
-
21
Institutional Holders of Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG) as of Q1 2024
As of 31 Mar 2024,
Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,303,060 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Versant Venture Management, LLC, Lynx1 Capital Management LP, Vestal Point Capital, LP, New Leaf Venture Partners, L.L.C., Erste Asset Management GmbH, VANGUARD GROUP INC, TANG CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, and ACADIAN ASSET MANAGEMENT LLC.
This page lists
48
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.